UBS Group Ceases to Be Substantial Shareholder in Starpharma

Starpharma Holdings Limited ( (AU:SPL) ) just unveiled an update.

UBS Group AG and its related bodies corporate have notified Starpharma Holdings Limited that they have ceased to be a substantial shareholder in the company as of 10 March 2026. The change in UBS’s relevant interest in Starpharma’s voting securities, detailed in the associated filing, indicates a reduction of its holdings below the substantial shareholding threshold, potentially altering the company’s share register composition and the profile of its institutional investor base.

The cessation follows a prior substantial holding notice lodged in late February and updated in early March, reflecting ongoing changes in UBS’s position over a short period. While the specific transaction details are contained in an appendix, the disclosure signals a shift in ownership dynamics that may influence market perceptions of Starpharma’s stock and the level of engagement from major financial institutions.

The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.

More about Starpharma Holdings Limited

Starpharma Holdings Limited is an Australian biopharmaceutical company focused on developing and commercialising pharmaceutical and life science products. The company is known for its work in novel drug delivery and dendrimer-based technologies targeting healthcare and therapeutic markets.

Average Trading Volume: 957,670

Technical Sentiment Signal: Buy

Current Market Cap: A$168M

See more data about SPL stock on TipRanks’ Stock Analysis page.